Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Ashley Weigle

Physician Assistant Castle Rock, CO Physician Assistant

NPI 1073941159 CMS profile 10676678

4386 Trail Boss Dr Ste A, Castle Rock, CO 80104

Open in the dashboard

General payments

$6,068

337 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ashley Weigle of Castle Rock, CO is reported in the CMS Open Payments database as having received $6,068 across 337 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,235 64
2024 General $1,226 71
2023 General $1,207 65
2022 General $1,141 60
2021 General $1,259 77

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ashley Weigle
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Ashley Weigle were reported at $1,235. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Ashley Weigle Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,259 $132 $37–$438 $132
2022 $1,141 $155 $48–$522 $149
2023 $1,207 $167 $52–$557 $160
2024 $1,226 $178 $55–$600 $164
2025 $1,235 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,128 67 payments
  2. Novo Nordisk Inc $945 48 payments
  3. AstraZeneca Pharmaceuticals LP $725 37 payments
  4. Pfizer Inc. $514 36 payments
  5. Lilly USA, LLC $454 31 payments
  6. GlaxoSmithKline, LLC. $198 9 payments
  7. Amgen Inc. $185 10 payments
  8. Merck Sharp & Dohme Corporation $152 9 payments
  9. Sanofi Pasteur Inc. $151 6 payments
  10. Esperion Therapeutics, Inc. $145 7 payments
  11. Other $1,472 77 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,038 336 payments
  2. Education $30 1 payment
Products named General payments · program years 2021–2025
  1. VRAYLAR $483 23 payments
  2. UBRELVY $460 29 payments
  3. Ozempic $355 22 payments
  4. RYBELSUS $355 22 payments
  5. ZAVZPRET $326 21 payments
  6. NURTEC ODT $309 21 payments
  7. Wegovy $303 13 payments
  8. QULIPTA $260 16 payments
  9. MOUNJARO $220 13 payments
  10. FARXIGA $200 10 payments
  11. Other $4,830 278 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 49 drugs

Part D claims

1,278

Median for Physician Assistant: 241

Drug cost

$112,790

Median for Physician Assistant: $4,110

Branded share of claims

16%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 37 $47,835
Ozempic Semaglutide Brand 11 $24,959
Eliquis Apixaban Brand 14 $20,610
Premarin Estrogens, Conjugated Brand 13 $7,053
Synthroid Levothyroxine Sodium Brand 14 $1,005
Omeprazole Generic 69 $1,003
Pregabalin Generic 17 $928
Levothyroxine Sodium Generic 107 $805
Gabapentin Generic 40 $790
Oxybutynin Chloride Er Oxybutynin Chloride Brand 19 $748

The 10 drugs with the highest cost, of 49 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NURTEC ODT
  • PFIZER INC. $98
$98 — —
ZAVZPRET
  • PFIZER INC. $98
$98 — —
Wegovy
  • Novo Nordisk Inc $68
$68 — —
ZEPBOUND
  • Lilly USA, LLC $53
$53 — —
MOUNJARO
  • Lilly USA, LLC $52
$52 37 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

337 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record